Volume 34, Issue 1 (2-2020)                   Med J Islam Repub Iran 2020 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghili R, Honardoost M, Khamseh M E. COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities. Med J Islam Repub Iran 2020; 34 (1) :1011-1016
URL: http://mjiri.iums.ac.ir/article-1-6799-en.html
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
Rokhsareh Aghili , Maryam Honardoost , Mohammad E Khamseh
Endocrine Research Center, Institute of Endocrinology and Metabolism, & Cardio-Oncology Research Center, Rajaie Cardiovascular Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran , honardoost.m@iums.ac.ir
Abstract:   (1537 Views)
The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.
Keywords: COVID-19, Associated comorbidities, Treatment, ACE2 inhibitors, Type 2 diabetes
Full-Text [PDF 640 kb]   (415 Downloads)    
Type of Study: Review Article | Subject: Endocrinology
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.